查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712508

全球人体肝臟模型市场 - 2025-2033

Global Human Liver Models Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球人体肝臟模型市场规模达 13.7 亿美元，预计到 2033 年将达到 37.6 亿美元，在 2025-2033 年预测期内的复合年增长率为 12.3%。

人体肝臟模型是一种先进的结构，旨在模仿人体肝臟的生理和功能属性。这些模型主要用于研究药物毒性、肝臟疾病和肝臟解剖的复杂空间动态。复杂的人类肝臟模型可以以多种形式存在，例如类器官、3D 生物列印组织和肝臟晶片系统，所有这些模型都致力于从分子水平及更高水平复製人类肝臟生理学。

市场动态：

驾驶员和约束装置

肝病盛行率不断上升

肝病盛行率的不断上升是全球人体肝臟模型市场扩张的主要动力。发病率的上升迫切需要先进的研究工具，以提高我们对肝功能、疾病过程和药物交互作用的了解。

根据 2022 年 3 月《BMC 内分泌疾病》研究出版物，包括非酒精性脂肪肝病 (NAFLD)、病毒性肝炎、肝硬化和肝癌在内的慢性肝病的全球盛行率正在显着增加。例如，NAFLD已成为西方国家最常见的慢性肝病，影响全球约25％的人口。

此外，主要参与者的策略（例如合作伙伴关係、协作、宣传计划和创新产品发布）将推动该市场的成长。例如，2024年2月，合作开发用于药物毒性筛选的肝类器官是一项重要倡议，旨在提高药物开发过程中新药的安全性和有效性。该计画由辛辛那提儿童医院的 CuSTOM 加速器实验室牵头，是丹纳赫集团「Beacons」计画的一部分，专注于利用人类肝臟类器官作为临床前测试工具的潜力。

同样，2023 年 2 月，CN Bio 推出了 Physio Mimix 单一器官高通量 (HT) 系统，旨在提高预测性人体肝臟模型在药物发现中的使用。这项创新系统解决了阻碍这些模型广泛应用的现有挑战，使研究人员能够进行更大规模的比较研究，以评估开发过程早期阶段候选药物的功效、性质和安全性。

人体肝臟模型成本高昂

全球人体肝臟模型市场面临的主要挑战之一是开发和维护先进模型的高成本。 3D 生物列印、类器官和器官晶片系统等技术处于创新的前沿，但需要复杂的基础设施和专门的设备。这些平台不仅采购成本高昂，而且操作和维护成本也高昂，涉及先进的材料、消耗品和高精度。这使得许多新兴市场的小型研究机构、新创公司和设施在经济上无法获得这些资金。

此外，取得和使用人类来源的细胞（尤其是原代人类肝细胞）的成本非常高。由于道德限制、捐赠者有限以及严格的品质控制标准，这些细胞很难获得。维持其在培养中的生存力和功能会增加进一步的费用，因为它需要丰富的培养基、生长因子和严格控制的环境条件。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的程式码片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 肝病盛行率不断上升
      • 器官晶片技术与先进3D生物列印技术的发展
    • 限制
      • 人体肝臟模型成本高昂
      • 专业技能人才短缺
    • 机会
      • 虚拟临床试验的扩展
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • 最新进展与突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：人体肝臟模型市场（依产品类型）

  • 2D模型
  • 3D模型
    • 肝臟晶片
    • 肝臟类器官
    • 球体
    • 3D生物列印

第六章：人体肝臟模型市场（依应用）

  • ADME研究
  • 药物研发
  • 毒理学测试
  • 疾病模型
  • 其他的

第七章：人体肝臟模型市场（以最终用户划分）

  • 学术及研究机构
  • 製药和生物技术公司
  • 合约研究组织

第八章：人体肝臟模型市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Corning Incorporated
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • BioIVT LLC
  • Emulate Inc.
  • InSphero
  • Organovo Holdings Inc.
  • MIMETAS BV
  • CN Bio Innovations Ltd
  • CELLINK
  • Visikol, Inc.
  • Cyprotex PLC

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: BT5842

The global human liver models market reached US$ 1.37 billion in 2024 and is expected to reach US$ 3.76 billion by 2033, growing at a CAGR of 12.3% during the forecast period of 2025-2033.

A human liver model is an advanced construct designed to imitate the physiological and functional attributes of the human liver. These models are mainly utilized for investigating drug toxicity, liver diseases, and the intricate spatial dynamics of liver anatomy. Sophisticated human liver models can exist in various formats, such as organoids, 3D bioprinted tissues, and liver-on-a-chip systems, all striving to replicate human liver physiology from the molecular level and beyond.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Liver Diseases

The growing prevalence of liver diseases is a key driver behind the expansion of the global human liver models market. This rising incidence generates an urgent need for sophisticated research tools that can improve our understanding of liver function, disease processes, and drug interactions.

According to a BMC Endocrine Disorders research publication in March 2022, the global prevalence of chronic liver conditions, including non-alcoholic fatty liver disease (NAFLD), viral hepatitis, cirrhosis, and liver cancer, is increasing significantly. For example, NAFLD has emerged as the most prevalent chronic liver disorder in Western countries, affecting roughly 25% of the global population.

Furthermore, key players' strategies, such as partnerships & collaborations, awareness programs, and innovative product launches, would drive this market growth. For instance, in February 2024, the collaboration to develop liver organoids for drug toxicity screening is a significant initiative aimed at improving the safety and efficacy of new medications during the drug development process. This project, led by the CuSTOM Accelerator Lab at Cincinnati Children's Hospital, is part of Danaher Corporation's "Beacons" program and focuses on harnessing the potential of human liver organoids as a tool for preclinical testing.

Similarly, in February 2023, CN Bio introduced the Physio Mimix Single-organ Higher Throughput (HT) System, aimed at improving the use of predictive human liver models in drug discovery. This innovative system tackles existing challenges that hinder the widespread adoption of these models, allowing researchers to perform larger-scale comparative studies to evaluate the efficacy, disposition, and safety of drug candidates at earlier stages in the development process.

High Costs of Human Liver Models

One of the primary challenges facing the global human liver models market is the high cost associated with developing and maintaining advanced models. Technologies such as 3D bioprinting, organoids, and organ-on-a-chip systems are at the forefront of innovation but require sophisticated infrastructure and specialized equipment. These platforms are not only expensive to procure but also to operate and maintain, involving advanced materials, consumables, and a high degree of precision. This makes them financially inaccessible for many smaller research institutions, startups, and facilities in emerging markets.

In addition, the cost of sourcing and using human-derived cells, particularly primary human hepatocytes, is remarkably high. These cells are difficult to obtain due to ethical constraints, limited donor availability, and strict quality control standards. Maintaining their viability and function in culture adds further expenses, as it requires enriched media, growth factors, and tightly regulated environmental conditions.

Segment Analysis

The global human liver models market is segmented based on product type, application, end-user, and region.

Product Type:

The 3D models segment in product type is expected to dominate the global human liver models market with the highest market share

Conventional 2D cell cultures, which frequently do not accurately mimic the intricate architecture and microenvironment of human tissues, 3D liver models offer a more authentic representation of in vivo conditions. These models integrate various cell types and structural elements that are crucial for effectively studying liver function and drug responses. Recent developments in 3D bioprinting methods have enhanced the viability and functionality of liver cells in these models. For instance, researchers have effectively printed liver tissues that incorporate vascular structures, facilitating improved delivery of nutrients and oxygen, which is essential for sustaining cell health and function over extended periods.

Moreover, key players in the industry are more focused on the ongoing research studies on liver cells and investments that would propel this segment's growth in the market. For instance, in June 2024, Mini liver models, particularly the development of 3D liver spheroids, are set to improve the effectiveness of drug testing significantly. Researchers at King's College London (KCL) have developed a laboratory-grown Mini liver model that integrates liver cells with a synthetic nano scaffold. This novel approach enables the mini liver to more accurately replicate the structure and function of the human liver compared to conventional 2D cell culture models.

Similarly, in April 2024, Bayland Capital and CN Innovations Holdings Ltd, the founding shareholders, are set to invest $10 million and $5.5 million, respectively. This funding will support the expansion of product development and scaling efforts within the organization to meet the growing demand for Organ-on-a-Chip (OOC) solutions. These factors have solidified the segment's position in the global human liver models market.

Geographical Analysis

North America is expected to hold a significant position in the global human liver models market with the highest market share

The increasing prevalence of liver diseases, including non-alcoholic fatty liver disease (NAFLD), hepatitis, cirrhosis, and liver cancer, is a major factor driving the growth of the human liver model market. According to the American Liver Foundation, in September 2023, around 4.5 million adults in the U.S. were affected by liver disease. This rising incidence underscores the urgent need for advanced human liver models that can offer deeper insights into liver function and disease mechanisms, ultimately enhancing the drug discovery process.

Advancements in 3D bioprinting and organ-on-a-chip technologies have greatly enhanced the precision and effectiveness of human liver models. These innovations enable researchers to develop models that are more physiologically relevant and accurately replicate human liver conditions. Moreover, in this region, key players' strategies such as partnerships & collaboration, well-advanced healthcare infrastructure, R&D activities, government initiatives & regulatory bodies' support are driving this market growth.

For instance, in January 2024, CN Bio and Altis Biosystems entered into a strategic partnership to create a next-generation human Gut/Liver in vitro model aimed at improving ADME (Absorption, Distribution, Metabolism, and Excretion) studies. This collaboration combines Altis' RepliGut Planar-Jejunum model with CN Bio's PhysioMimix Liver-on-a-Chip, resulting in a comprehensive microphysiological system (MPS) that simulates inter-organ communication and accurately reflects the oral drug administration process.

Additionally, in September 2023, UC Davis Health introduced a new liver transplant program, representing a significant advancement in its transplant services. This program is set to resume operations after being temporarily closed, with plans to begin accepting patients in the spring of 2023. Thus, the above factors are consolidating the region's position as a dominant force in the global human liver models market.

Competitive Landscape

The major global players in the human liver models market include Corning Incorporated, BioIVT LLC, Emulate Inc., InSphero, Organovo Holdings Inc., MIMETAS B.V., CN Bio Innovations Ltd, CELLINK, Visikol, Inc., and Cyprotex PLC, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global human liver models market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Liver Diseases
      • 3.1.1.2. Growth of Organ-on-a-Chip Technology and Advanced 3D Bioprinting
    • 3.1.2. Restraints
      • 3.1.2.1. High Costs of Human Liver Models
      • 3.1.2.2. Shortage of Skilled Professionals
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion of Virtual Clinical Trials
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics
  • 4.12. Key Opinion Leaders

5. Human Liver Models Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. 2D Models*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. 3D Models
    • 5.3.1. Liver-on-a-Chip
    • 5.3.2. Liver Organoids
    • 5.3.3. Spheroids
    • 5.3.4. 3D Bioprinting

6. Human Liver Models Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. ADME Studies*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Drug Discovery
  • 6.4. Toxicology Testing
  • 6.5. Disease Modelling
  • 6.6. Others

7. Human Liver Models Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Academic & Research Institutes*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Pharmaceutical & Biotechnology Companies
  • 7.4. Contract Research Organizations

8. Human Liver Models Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Corning Incorporated*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. BioIVT LLC
  • 10.3. Emulate Inc.
  • 10.4. InSphero
  • 10.5. Organovo Holdings Inc.
  • 10.6. MIMETAS B.V.
  • 10.7. CN Bio Innovations Ltd
  • 10.8. CELLINK
  • 10.9. Visikol, Inc.
  • 10.10. Cyprotex PLC

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us